Nice & Green participates in the IPO of the French biotech MaaT Pharma now listed on Euronext Paris
Nice & Green, the Swiss investment firm, announces today its participation in the Initial Public Offering (IPO) operation of the French biotech MaaT Pharma, which started trading on Euronext Paris on November 8, 2021.
The proceeds of this IPO will enable MaaT Pharma to implement its clinical and industrial development plan in the field of microbiota modulation in oncology, to broaden its product portfolio by developing new innovative microbiota-based therapies, and to accelerate its growth.
Nice & Green is delighted to be supporting MaaT Pharma in its determination to become a reference player in the world of microbiota in oncology for the benefit of millions of patients. This investment initiative falls under Nice & Green’s mission towards closing the gap of SMEs financing by efficiently securing the funds needed for their long-term growth.
Based on Euronext’s reporting, this IPO transaction raised €31.5 million altogether from both institutional and private investors.
About MaaT Pharma
MaaT Pharma (EPA:MAAT) is a French clinical stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer. The company is currently developing three prospective drugs, the most advanced of which is ready to enter Phase 3 clinical trials, to improve the chances of survival of patients with acute graft-versus-host disease. Find out more at maatpharma.com.
About Nice & Green
Nice & Green is a privately held Swiss investment firm providing innovative and tailor-made financing solutions for small and mid-sized listed companies. Nice & Green helps ambitious companies secure the funding needed for their growth and strives to establish long-term financial partnerships with them. Find out more at nicengreen.ch.
Contact Information
Michèle Aouad
Head of Marketing & Communications
maouad@nicengreen.ch
+41 (0)22 361 36 97